NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) posted its earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

5 brokers have issued 12-month price objectives for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $40.00. On average, they expect Y-mAbs Therapeutics' share price to reach $39.25 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

Headlines about YMAB stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,650,000 shares, an increase of 55.7% from the December 15th total of 1,060,000 shares. Based on an average daily trading volume, of 269,200 shares, the short-interest ratio is presently 6.1 days. Currently, 8.5% of the shares of the company are sold short. View Y-mAbs Therapeutics' Current Options Chain.

Some companies that are related to Y-mAbs Therapeutics include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Deciphera Pharmaceuticals (DCPH) and Ultragenyx Pharmaceutical (RARE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Evoke Pharma (EVOK), JD.Com (JD), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Alibaba Group (BABA) and AVEO Pharmaceuticals (AVEO).

(YMAB) raised $80 million in an initial public offering on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Strs Ohio (0.06%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

YMAB stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $35.00.

Y-mAbs Therapeutics has a market capitalization of $1.39 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]